Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemophilus influenzae type b Capsular Polysaccharide-Protein Conjugate (Hib conjugate)
- Target
- Hib conjugate
- Molecular classification
- Glycoconjugate, Inactivated vaccine, Toxoid
01
Overview
The Haemophilus influenzae type b (Hib) capsular polysaccharide-protein conjugate is the active component in Hib conjugate vaccines, designed to prevent invasive diseases caused by H. influenzae type b bacteria. The vaccine consists of the polyribosylribitol phosphate (PRP) capsule polysaccharide conjugated to a carrier protein to enhance immunogenicity, particularly in infants. Common carrier proteins include tetanus toxoid, diphtheria toxoid, Neisseria meningitidis outer membrane protein, and diphtheria mutant carrier protein CRM197. The conjugation process enables the immune system to recognize the PRP antigen as a T-cell dependent antigen, leading to robust antibody production and immunological memory against Hib bacteria. It is administered intramuscularly as part of routine childhood immunization schedules.
- Other names
- Hib vaccinePRP-TPRP-DPRP-OMPHbOCActHIBHibtiterPedvaxHIBMenhibrix
02
Mechanism of action
The conjugate vaccine elicits a T-cell dependent immune response, leading to production of antibodies against the capsular polysaccharide (PRP) of Haemophilus influenzae type b.
03
Biological functions
Induction of humoral immunityB cell activationT cell activationImmunological memory
04
Disease associations
Prevention of Haemophilus influenzae type b infectionsPrevention of MeningitisPrevention of EpiglottitisPrevention of PneumoniaPrevention of PericarditisPrevention of Septic Arthritis
05
Safety considerations
Local injection site reactionsRare allergic reactions
06
Biomarkers
Anti-PRP antibody titers
Beyond the preview
Go deeper on Haemophilus influenzae type b Capsular Polysaccharide-Protein Conjugate (Hib conjugate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b Capsular Polysaccharide-Protein Conjugate (Hib conjugate).